Who is sponsoring NCT04771910?

NCT04771910 is sponsored by University Hospital, Antwerp.

What drugs are being tested in NCT04771910?

Interventions in NCT04771910: Topical cream with live probiotic bacteria, Placebo cream.

What condition does NCT04771910 study?

NCT04771910 studies Atopic Dermatitis.

Is NCT04771910 still recruiting?

NCT04771910 is currently status unknown. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT04771910

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Skin Microbiome and the Potential of a Topical Probiotic Cream for Atopic Dermatitis

Status unknown NA Last updated 28 April 2021

What this trial tests

NA trial testing Topical cream with live probiotic bacteria in Atopic Dermatitis in 40 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
1 January 2022

1 January 2022

Quick facts

Lead sponsor	University Hospital, Antwerp
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	1 January 2021
Primary completion	1 January 2022
Estimated completion	1 January 2022
Sites	1 location across Belgium

Drugs / interventions tested

Topical cream with live probiotic bacteria
Placebo cream

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

University Hospital, Antwerp

Who can join

6 Months and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The skin microbiome of atopic dermatitis patients and healthy volunteers will be studies by collecting and analysing skin swabs on different timepoint. Additional, effort will be made to isolate and characterize Lactobacillus spp. and other beneficial micro-organisms on the skin. Second aim of this study is to evaluate a topical probiotic cream in atopic dermatitis treatment. A double-blind placebo-controlled intervention study will be performed in parallel with the skin microbiome analysis. Both clinical effect on the symptoms of atopic dermatitis and effect on the skin microbiome and survival of beneficial bacteria on the skin will be evaluated.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The skin microbiome in pediatric atopic dermatitis and food allergy.
Tham EH, Chia M, Riggioni C, Nagarajan N, et al · · 2024 · cited 18× · PMID 38308490 · DOI 10.1111/all.16044
Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species.
Delanghe L, De Boeck I, Van Malderen J, Allonsius CN, et al · · 2024 · cited 6× · PMID 39390034 · DOI 10.1038/s41598-024-74513-2
The inner elbow skin microbiome contains <i>Lactobacillus</i> among its core taxa and varies with age, season and lifestyle.
Delanghe L, De Boeck I, Van Malderen J, Gehrmann T, et al · · 2024 · cited 1× · PMID 39741954 · DOI 10.20517/mrr.2024.23
Mild atopic dermatitis is characterized by increase in non-staphylococcus pathobionts and loss of specific species
Delanghe L, De Boeck I, Malderen JV, Allonsius CN, et al · · 2024 · DOI 10.21203/rs.3.rs-3853989/v1

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other University Hospital, Antwerp trials

Trials by the same sponsor.

NCT07455422 — A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurr · NA · not yet recruiting
NCT07020715 — A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis · Phase 2 · not yet recruiting
NCT07443761 — Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital. · active not recruiting
NCT06372847 — DISE-HNS Effect Study · NA · recruiting
NCT07189091 — CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04771910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Antwerp
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04771910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing